Phreesia (PHR) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
28 May, 2026Executive summary
Revenue grew 13% year-over-year to $130.9 million in Q1 FY2027, led by strong payment and network solutions performance and supported by AccessOne integration.
Net income reached $3 million, marking a return to profitability and a significant year-over-year improvement.
Adjusted EBITDA rose to $30.5 million, up 46% year-over-year, with margin at 23%.
Free cash flow improved to $16.4 million, more than doubling year-over-year.
Strategic focus on integrating AccessOne, expanding payment solutions, leveraging AI, and launching ProviderConnect.
Financial highlights
Payment solutions revenue surged 40% year-over-year to $41.9 million, reflecting the AccessOne acquisition.
Network solutions revenue grew 15% to $36.3 million, with ProviderConnect contributing to growth.
Subscription and related services revenue was $52.7 million, down 3% due to one-time adjustments.
Average Healthcare Services Clients (AHSCs) increased 7% to 4,708, with total revenue per AHSC up 6% to $27,811.
Free cash flow and operating cash flow reached $16.4 million and $23.9 million, respectively.
Outlook and guidance
Fiscal 2027 revenue guidance maintained at $510–$520 million, including $37 million from AccessOne.
Adjusted EBITDA outlook unchanged at $125–$135 million.
Expect mid-single-digit AHSC growth and low-single-digit growth in revenue per AHSC for fiscal 2027.
Restructuring plan implemented in May 2026 to reduce operating expenses and drive annualized run-rate savings.
Cautious on network solutions spend in the second half due to client budget variability and regulatory impacts.
Latest events from Phreesia
- Proxy seeks approval for director elections, auditor ratification, and executive pay, highlighting governance and ESG.PHR
Proxy filing14 May 2026 - Key votes include director elections, auditor ratification, and executive pay approval.PHR
Proxy filing14 May 2026 - FY27 revenue guidance lowered on pharma headwinds, but margin and cash flow outlooks remain strong.PHR
Q4 202630 Mar 2026 - 19% revenue growth, positive free cash flow, and improved EBITDA mark a strong Q2 FY25.PHR
Q2 202522 Jan 2026 - Revenue up 17%, net loss narrowed, and Adjusted EBITDA positive with strong outlooks ahead.PHR
Q3 202511 Jan 2026 - Double-digit revenue growth, positive cash flow, and strong 2026 outlook maintained.PHR
Q4 202526 Dec 2025 - Q3 FY2026 saw 13% revenue growth, profitability, and a major acquisition completed.PHR
Q3 20269 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with focus on governance and ESG.PHR
Proxy Filing1 Dec 2025 - Key votes include director elections, auditor ratification, and executive pay approval.PHR
Proxy Filing1 Dec 2025